Bromo-DragonFLY

Jump to: navigation, search
Bromo-DragonFLY
Chemical name Bromo-benzodifuranyl-isopropylamine or
(1-(8-bromobenzo[1,2-b;4,5-b']difuran-
4-yl)-2-aminopropane
Chemical formula C13H12BrNO2
Molecular mass 294.14 g/mol
Melting point decomposes at 240 °C (hydrochloride)
CAS number -
SMILES N[C@H](C)CC1=C(OC=C2)C2=
C(Br)C3=C1C=CO3 (R-isomer)

WikiDoc Resources for Bromo-DragonFLY

Articles

Most recent articles on Bromo-DragonFLY

Most cited articles on Bromo-DragonFLY

Review articles on Bromo-DragonFLY

Articles on Bromo-DragonFLY in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Bromo-DragonFLY

Images of Bromo-DragonFLY

Photos of Bromo-DragonFLY

Podcasts & MP3s on Bromo-DragonFLY

Videos on Bromo-DragonFLY

Evidence Based Medicine

Cochrane Collaboration on Bromo-DragonFLY

Bandolier on Bromo-DragonFLY

TRIP on Bromo-DragonFLY

Clinical Trials

Ongoing Trials on Bromo-DragonFLY at Clinical Trials.gov

Trial results on Bromo-DragonFLY

Clinical Trials on Bromo-DragonFLY at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Bromo-DragonFLY

NICE Guidance on Bromo-DragonFLY

NHS PRODIGY Guidance

FDA on Bromo-DragonFLY

CDC on Bromo-DragonFLY

Books

Books on Bromo-DragonFLY

News

Bromo-DragonFLY in the news

Be alerted to news on Bromo-DragonFLY

News trends on Bromo-DragonFLY

Commentary

Blogs on Bromo-DragonFLY

Definitions

Definitions of Bromo-DragonFLY

Patient Resources / Community

Patient resources on Bromo-DragonFLY

Discussion groups on Bromo-DragonFLY

Patient Handouts on Bromo-DragonFLY

Directions to Hospitals Treating Bromo-DragonFLY

Risk calculators and risk factors for Bromo-DragonFLY

Healthcare Provider Resources

Symptoms of Bromo-DragonFLY

Causes & Risk Factors for Bromo-DragonFLY

Diagnostic studies for Bromo-DragonFLY

Treatment of Bromo-DragonFLY

Continuing Medical Education (CME)

CME Programs on Bromo-DragonFLY

International

Bromo-DragonFLY en Espanol

Bromo-DragonFLY en Francais

Business

Bromo-DragonFLY in the Marketplace

Patents on Bromo-DragonFLY

Experimental / Informatics

List of terms related to Bromo-DragonFLY


Overview

Bromo-DragonFLY, also known as ABDF, is a psychedelic hallucinogenic drug somewhat related to the phenethylamine family. Bromo-DragonFLY is considered an extremely potent hallucinogen, only slightly less potent than LSD with a normal dose in the region of 200μg to 800μg, and it has an extremely long duration of action. It is not illegal anywhere in the world at this time (except in Sweden, where it is classified as an narcotic) although it may be considered a controlled substance analogue under US and Australian drug laws. Bromo-DragonFLY has a stereocenter and R-(-)-bromo-DragonFLY is the more active stereoisomer.

Pharmacology

The hallucinogenic effect of bromo-DragonFLY is mediated by its agonist activity at the 5-HT2A serotonin receptor. Bromo-DragonFLY also has a high binding affinity for the 5-HT2B and 5-HT2C serotonin receptor. User reports of the effects of bromo-DragonFLY suggest that while the effects are very long lasting, they tend to be somewhat milder than those of traditional hallucinogens such as LSD, suggesting that while bromo-DragonFLY is a full agonist at the 5HT2A receptor, it may not be activating the intracellular signalling pathways following receptor binding as effectively as LSD.

History

Bromo-DragonFLY was first synthesized by Matthew A. Parker in the laboratory of David E. Nichols in 1998.

Deaths

Bromo-DragonFLY can sometimes be found on "blotters" (small bits of paper containing the substance) reminiscent of the most commonly found form of LSD, thus making it difficult to identify which substance it is carrying. Erowid reports two news stories, one in Sweden and one in Norway, about deaths possibly involved with bromo-dragonFLY. Erowid Bromo-Dragonfly vault

See also

References

  • 'A novel (benzodifuranyl)aminoalkane with extremely potent activity at the 5-HT2A receptor' by M. A. Parker, D. Marona-Lewicka, V. L. Lucaites, D. L. Nelson, and D. E. Nichols in J. Med. Chem. 41(26): 5148-5149 (1998) DOI: 10.1021/jm9803525
  • 'Enantiospecific synthesis and pharmacological evaluation of a series of super-potent, conformationally restricted 5-HT2A/2C receptor agonists' by J. J. Chambers, D. M. Kurrasch-Orbaugh, M. A. Parker, and D. E. Nichols in J. Med. Chem. 44(6): 1003-1010 (2001) DOI: 10.1021/jm000491y

External links




Linked-in.jpg